|本期目录/Table of Contents|

[1]宋景春.重症患者纤维蛋白原缺乏症的现代诊疗观点[J].医学研究与战创伤救治(原医学研究生学报),2018,20(05):454-458.[doi:10.3969/j.issn.1672-271X.2018.05.002]
　SONG Jing-chun.Fibrinogen deciency in critical ill patients: Current perspectives[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(05):454-458.[doi:10.3969/j.issn.1672-271X.2018.05.002]
点击复制

重症患者纤维蛋白原缺乏症的现代诊疗观点()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第20卷
期数:
2018年05期
页码:
454-458
栏目:
出版日期:
2018-09-18

文章信息/Info

Title:
Fibrinogen deciency in critical ill patients: Current perspectives
作者:
宋景春
作者单位：330002南昌，解放军第九四医院重症医学科
Author(s):
SONG Jing-chun
(Intensive Care Unit, the 94th Hospital of PLA, Nanchang 330002, Jiangxi, China)
关键词:
纤维蛋白原; 异常; 重症; 遗传性; 获得性
Keywords:
fibrinogen; deciency; critical care; acquired; congenital
分类号:
R591.2
DOI:
10.3969/j.issn.1672-271X.2018.05.002
文献标志码:
A
摘要:
纤维蛋白原缺乏症是危重症患者经常出现的凝血疾病。该疾病病因众多，机制复杂，临床既可表现为血栓，又可表现为出血，不易明确诊断。一旦治疗不及时，就容易造成不良预后。文章主要对危重患者纤维蛋白原缺乏症的分型、病理生理、诊断方法 和治疗要点进行评述。
Abstract:
Critically ill patients often suffered fibrinogen deciency. The disease has numerous etiologies and complicated mechanisms. The clinical features were manifested as thrombosis or hemorrhage, which made clinical diagnosis difficult and were easily to cause death. This article briefly describes the classification, pathophysiology, diagnosis and treatment of fibrinogen deciency in critically ill patients.

参考文献/References:

[1]Tiscia GL, Margaglione M. Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders[J]. Int J Mol Sci, 2018, 19(6). pii: E1597.
[2]Mosesson MW, Siebenlist KR, Meh DA.The structure and biological features of brinogen and brin[J]. Ann N Y Acad Sci, 2001, 936:11-30.
[3]Acharya SS, Dimichele DM.Rare inherited disorders of brinogen[J]. Haemophilia, 2008, 14:1151-1158.
[4]Mosesson MW. Fibrinogen and fibrin structure and functions[J]. J Thromb Haemost, 2005, 3(8):1894-1904.
[5]Sproul EP, Hannan RT, Brown AC. Controlling Fibrin Network Morphology, Polymerization, and Degradation Dynamics in Fibrin Gels for Promoting Tissue Repair[J]. Methods Mol Biol, 2018, 1758:85-99.
[6]Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression[J]. Thromb Res, 2018, 164(Suppl 1):S54-S61.
[7]Kreuz W, Meili E, Peter-Salonen K, et al. Effcacy and tolerability of a pasteurised human brinogen concentrate in patients with congenital brinogen deciency[J]. Transfus Apher Sci, 2005,32:247-253.
[8]de Moerloose P, Neerman-Arbez M. Congenitalbrinogen disorders[J]. Semin Thromb Hemost, 2009, 35:356-366.
[9]de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update[J]. Semin Thromb Hemost, 2013, 39(6):585-595.
[10]Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation[J]. Blood Rev, 2015, 29(1):17-24.
[11]Peyvandi F. Epidemiology and treatment of congenital brinogen deciency[J]. Thromb Res, 2012, 130 (Suppl 2):S7-S11.
[12]Krammer B, Anders O, Nagel HR, et al.Screening of dysbrinogenaemia using the brinogen function versus antigen concentration ratio[J]. Thromb Res, 1994, 76(6): 577-579.
[13]Kalina U, Stohr HA, Bickhard H, et al. Rotational thromboelastography for monitoring of brinogen concentrate therapy in brinogen deciency[J]. Blood Coagul Fibrinolysis, 2008, 19(8): 777-783.
[14]Wei A, Liao L, Xiang L, et al. Congenital dysfibrinogenaemia assessed by whole blood thromboelastography [J]. Int J Lab Hematol, 2018,40(4):459-465.
[15]Durila M, Luká P, Astraverkhava M, et al. Evaluation of fibrinogen concentrates and prothrombin complex concentrates on coagulation changes in a hypothermic in vitro model using thromboelastometry and thromboelastography [J].Scand J Clin Lab Invest, 2015,75(5):407-414.
[16] Grottke O, Braunschweig T, Henzler D, et al.Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury[J]. Crit Care, 2010,14(2): R62.
[17]Faraday N. Fibrinogen concentrate and allogeneic blood transfusion in high-risk surgery[J]. Anesthesiology, 2013,118(1):7-9.

相似文献/References:

[1]杨 玲.D-二聚体、纤维蛋白原及抗凝血酶Ⅲ联合检测对早期2型糖尿病肾病的诊断价值[J].医学研究与战创伤救治(原医学研究生学报),2015,17(04):402.[doi:10.3969/j.issn.1672-271X.2015.04.021]
　YANG Ling..The significance of detection of D-dimer, fibrinogen and antithrombin-Ⅲ in the patients with typy-2 diabetic nephropathy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(05):402.[doi:10.3969/j.issn.1672-271X.2015.04.021]
[2]胡雪玲,宋佳希,牛冬梅,等.纤维蛋白原、C-反应蛋白和白细胞介素-6对肛周脓肿和肛瘘的辅助鉴别诊断价值[J].医学研究与战创伤救治(原医学研究生学报),2021,23(03):262.[doi:10.3969/j.issn.1672-271X.2021.03.009]
　HU Xue-ling,SONG Jia-xi,NIU Dong-mei,et al.Value of fibrinogen, C-reactive protein and interleukin 6 in diagnosis of perianal abscess and anal fistula[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(05):262.[doi:10.3969/j.issn.1672-271X.2021.03.009]
[3]陈美惠,贾佳,曹燕丽,等.抑郁症患者性激素异常及治疗的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(6):633.[doi:10.3969/j.issn.1672-271X.2021.06.016]
　CHEN Mei-hui,JIA Jia,CAO Yan-li,et al.Development on hormone abnormalities and treatment in patients with major depression[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(05):633.[doi:10.3969/j.issn.1672-271X.2021.06.016]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2018-09-20